Innovative biotechnologies: bacteriophages against infections

PhagoPROD, a pioneer production site in Europe

Architecte : AIA LIFE DESIGNERS - Photo ©G.Satre

Throught its PhagoPROD project, Pherecydes Pharma was chosen to illustrate the "Health" topic of the "InvestEU" European Communication campaign, as part of its support to innovative companies, via the "SME Instrument" H2020.

This project is dedicated to manufacture bacteriophages in Europe according to standards of pharmaceutical Good Manufacturing Pratices (GNP).


PhagoBurn, promising results


The results of PhagoBurn's first randomized, double-blind, multi-center clinical trial about phage therapy have just been published in The Lancet Infectious Disease.

This study demonstrates for the first time in an objective manner the action of phages to treat burns infected with Pseudomonas aeruginosa in severely burnt patients hospitalized in intensive care units.


Magali Vidal-Engaurran, Senior Pharmacist

Magali Vidal-Engaurran joins the Pherecydes Pharma Management Board to assume the position of Pharmacist – Qualified Person. With more than 15 years of experience, she will be responsible for setting up Good Manufacturing Practices (GMPs) within the production unit in Nantes and obtaining the status of a pharmaceutical manufacturer.


Salvage therapy

Four bacteriophages provided by Pherecydes Pharma to the Hospices Civils de Lyon have eliminated a bacterial infection induced by a Pseudomonas aeruginosa strain toto-resistant to antibiotics.

The description of this first case of compassionate treatment performed by Professor Tristan Ferry's team, in 2017, was published in the Journal of Antimicrobial in October 2018.


Bacteriophages: natural viruses of bacteria

They are harmless to eukaryote organisms (humans, animals, fishes, plants, insects, algae’s, etc).

When they recognize their bacterial target, they attach to its outer membrane, inject their genetic material and reproduce in their host to make new phages that get out and repeat the same cycle.

The lytic phages, those we are interested in, kill properly the bacteria as their progeny leave their host.


Antibiotic resistance:
a growing threat

Over the years, bacteria succeeded to develop mechanisms to evade antibiotics.

This antibiotic resistance is not new, but the phenomenon has increased dramatically during the past 10 to 15 years.

The increasing threat of resistance to existing antibiotics has been the major driver of the renewed interest in bacteriophage treatment.


In less than 10 years, Pherecydes Pharma has established itself as the champion of phage therapy. Following the development of the first pharmaceutical manufacturing process for bacteriophage, Pherecydes Pharma is the first company to have obtained authorizations for conducting a clinical trial to directly test its phages on hospitalized patients.

Jérôme Gabard, Chief Operating Officer at Pherecydes Pharma

Guy-Charles Fanneau de La Horie

Antibiotic resistance is a major health challenge in the years to come: 10 million people may die in 2050. New approaches are needed; Phage therapy represents the most promising hope. Pherecydes Pharma makes every effort to provide physicians and patients with effective treatments for the most serious bacterial infections.

Guy-Charles Fanneau de La Horie, Chief Executive Officer at Pherecydes Pharma


You can view all the information here

Pherecydes-Pharma is member of

Medicen Adebiotech Leem Beam Alliance Biocitech France Biotech